A study in humans identified the miR-1227-5p as a biomarker for recurrent myocardial infarction risk, finding it was downregulated in whole blood of patients with recurrent MI compared to those without in a replication cohort, with this differential expression remaining significant after false-discovery rate correction (FDR <0.1) [Onuoha et al. DOI:10.1111/cts.13307]. The investigation demonstrated that whole blood was a preferred sample source over plasma for miRNA profiling in coronary artery disease, as the miR-1227-5p was not significantly different in plasma samples.